Francesca Poggi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francesca Poggi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alice Laffusa
Gastroenterology and Endoscopy Unit, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
1 shared publication - Cesare Burti
Gastroenterology and Endoscopy Unit, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
1 shared publication - Chiara Viganò
Gastroenterology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy
1 shared publication - Laura Grieco
Division of Gastroenterology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
1 shared publication - Salvatore Greco
Gastroenterology and Endoscopy Unit, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
1 shared publication - Stefania Orlando
Gastroenterology and Endoscopy Unit, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2667
Inflammatory Bowel Disease: Understanding Therapeutic Effects of Distinct Molecular Inhibitors as the Key to Current and Future Advanced Therapeutic Strategies
The pathogenesis of Inflammatory Bowel Disease is complex and not completely understood, resulting from multifactorial interactions between genetic predisposition, environmental triggers, and dysregulation of both innate and adaptive immune responses. Cytokines, produced by dysregulated immune cells, trigger chronic intestinal inflammation leading to tissue damage, carcinogenesis, and disease perpetuation. Current advanced therapies—including tumor necrosis factor (TNF)-α antagonists, adhesion and trafficking inhibitors (such as anti-integrin agents and sphingosine-1-phosphate receptor modulators), interleukin inhibitors, and Janus kinase inhibitors—have improved patient outcomes, but targeting a single inflammatory pathway is often insufficient for long-term disease control. To further improve therapeutic efficacy, novel approaches are under investigation, including advanced combination therapies that simultaneously inhibit multiple pro-inflammatory pathways and microbiome-based treatments to restore intestinal homeostasis. In this evolving therapeutic scenario, precision medicine and advanced combination therapies appear promising for breaking through the current therapeutic ceiling. This review highlights current knowledge on the role of cytokines in IBD pathogenesis and explores how their modulation can modify and control disease course.
- 30 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2667
Open AccessInflammatory Bowel Disease: Understanding Therapeutic Effects of Distinct Molecular Inhibitors as the Key to Current and Future Advanced Therapeutic Strategies
The pathogenesis of Inflammatory Bowel Disease is complex and not completely understood, resulting from multifactorial interactions between genetic predisposition, environmental triggers, and dysregulation of both innate and adaptive immune responses. Cytokines, produced by dysregulated immune cells, trigger chronic intestinal inflammation leading to tissue damage, carcinogenesis, and disease perpetuation. Current advanced therapies—including tumor necrosis factor (TNF)-α antagonists, adhesion and trafficking inhibitors (such as anti-integrin agents and sphingosine-1-phosphate receptor modulators), interleukin inhibitors, and Janus kinase inhibitors—have improved patient outcomes, but targeting a single inflammatory pathway is often insufficient for long-term disease control. To further improve therapeutic efficacy, novel approaches are under investigation, including advanced combination therapies that simultaneously inhibit multiple pro-inflammatory pathways and microbiome-based treatments to restore intestinal homeostasis. In this evolving therapeutic scenario, precision medicine and advanced combination therapies appear promising for breaking through the current therapeutic ceiling. This review highlights current knowledge on the role of cytokines in IBD pathogenesis and explores how their modulation can modify and control disease course.